Delcath Systems Inc
DCTH
Market Cap$385.49M
Close$
$-3.80
132.6% downside
Current Fair Value
132.6% downsideOvervalued by 132.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $385.49 Million |
|---|---|
| Enterprise Value | $352.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 0.82 |
| Outstanding Shares | 35,786,813 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 176.69 |
|---|---|
| PEG | -147.7 |
| Price to Sales | 11.65 |
| Price to Book Ratio | 5.83 |
| Enterprise Value to Revenue | 5.14 |
| Enterprise Value to EBIT | 27.16 |
| Enterprise Value to Net Income | 158 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT? (melphalan hydrochloride for injection/hepatic delivery system), is d...